Product Description
Mechanisms of Action: CYP3A4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alaunos Therapeutics
Company Location: BOSTON MA 02129
Company CEO: Kevin S. Boyle
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Scleroderma, Systemic|Scleroderma, General|Scleroderma, Localized|Scleroderma, Diffuse|Brain Cancer|Glioma|Breast Cancer|Glioblastoma
Phase 1: Glioblastoma|Glioma|Astrocytoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| Protocol ATI001-102 Substudy | P1 |
Completed |
Glioblastoma |
2020-10-15 |
50% |
2022-02-10 |
Primary Endpoints |
| ATI001-102 | P1 |
Completed |
Glioblastoma|Glioma|Astrocytoma |
2019-08-01 |
2% |
2022-02-10 |
Primary Endpoints|Treatments |
| ATI001-102 EXP Substudy 2.0 | P1 |
Completed |
Glioblastoma |
2019-04-02 |
12% |
2022-02-10 |
Primary Endpoints|Treatments |
| ATI001-103 | P2 |
Terminated |
Brain Cancer|Glioma |
2021-09-10 |
50% |
2022-02-10 |
Primary Endpoints |
| ATI001-204 | P2 |
Terminated |
Glioblastoma |
2021-08-05 |
50% |
2025-04-19 |
Primary Endpoints |
| Morphea | P2 |
Terminated |
Scleroderma, Localized|Scleroderma, Systemic|Scleroderma, Diffuse|Scleroderma, General |
2020-09-23 |
9% |
2022-06-25 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| ATI001-203 | P2 |
Completed |
Breast Cancer |
2016-07-01 |
2022-02-10 |
Primary Endpoints|Treatments |